Immunocompromised COVID-19 patient successfully treated with vaccine: Case report

However, Rachel E. Bradley, University Hospital of Wales, Cardiff, UK, and colleagues wrote, "further studies are needed to assess the reproducibility and generalizability of the findings, particularly given the likely heterogeneity of vaccine-induced immune response across the spectrum of inborn errors of immunity." 

He first tested positive in December 2020 and had few symptoms at first, with the most noticeable being a lack of taste and smell. He then told his immunologist, who expressed concern that people with an impaired immune system could remain contagious for longer than usual. He was then given at-home swab kits to monitor his status. The symptoms slowly became worse over time.

After nearly 5 months, doctors decided to give him the two-dose Pfizer vaccine, with each dose 1 month apart. They saw a strong antibody response and a strong T-cell response. Finally, the patient tested negative 72 days after the first vaccine dose and 218 days since he first tested positive.

"This case underlines persistent SARS-CoV-2 infection as an important outcome in immunodeficient individuals, beyond commonly used metrics of mortality or critical illness," the team concluded. 

Reference:

Bradley, R.E., Ponsford, M.J., Scurr, M.J. et al. Persistent COVID-19 Infection in Wiskott-Aldrich Syndrome Cleared Following Therapeutic Vaccination: a Case Report. J Clin Immunol 42, 32–35 (2022). https://doi.org/10.1007/s10875-021-01158-5